AKO Capital LLP Takes Position in Illumina, Inc. (NASDAQ:ILMN)

AKO Capital LLP purchased a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 495,286 shares of the life sciences company's stock, valued at approximately $66,185,000. Illumina makes up about 0.9% of AKO Capital LLP's holdings, making the stock its 24th biggest position. AKO Capital LLP owned approximately 0.31% of Illumina at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of ILMN. Norges Bank bought a new stake in Illumina during the fourth quarter worth about $228,714,000. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in Illumina during the 4th quarter worth approximately $493,000. Elo Mutual Pension Insurance Co increased its holdings in Illumina by 10.1% during the 4th quarter. Elo Mutual Pension Insurance Co now owns 15,581 shares of the life sciences company's stock valued at $2,082,000 after purchasing an additional 1,431 shares in the last quarter. WINTON GROUP Ltd raised its position in Illumina by 169.6% in the 4th quarter. WINTON GROUP Ltd now owns 38,550 shares of the life sciences company's stock valued at $5,151,000 after purchasing an additional 24,249 shares during the last quarter. Finally, Korea Investment CORP raised its position in Illumina by 92.9% in the 4th quarter. Korea Investment CORP now owns 70,588 shares of the life sciences company's stock valued at $9,433,000 after purchasing an additional 34,000 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Trading Up 0.1 %

NASDAQ:ILMN traded up $0.09 during trading hours on Tuesday, hitting $79.43. The stock had a trading volume of 607,888 shares, compared to its average volume of 2,203,887. The business's 50 day moving average is $101.65 and its 200-day moving average is $126.49. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company has a market cap of $12.58 billion, a price-to-earnings ratio of -10.34, a P/E/G ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a one year low of $77.54 and a one year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ILMN. Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Stephens restated an "overweight" rating and issued a $156.00 price objective on shares of Illumina in a research report on Tuesday, March 11th. Canaccord Genuity Group dropped their target price on shares of Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a research note on Tuesday, March 11th. Piper Sandler raised their price target on shares of Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Finally, Morgan Stanley decreased their price objective on Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.